- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05327114
Nipokalimabin teho- ja turvallisuustutkimus aikuisilla, joilla on krooninen tulehduksellinen demyelinisoiva polyneuropatia (CIDP)
Vaihe 2/3, monivaiheinen, monikeskus, satunnaistettu, kaksoissokkoutettu, lumekontrolloitu rinnakkaisryhmävieroitustutkimus kroonista tulehduksellista demyelinisoivaa polyneuropatiaa (CIDP) sairastaville aikuisille annetun nipokalimabin tehon ja turvallisuuden arvioimiseksi
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 3
Laajennettu käyttöoikeus
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Study Contact
- Puhelinnumero: 844-434-4210
- Sähköposti: Participate-In-This-Study1@its.jnj.com
Opiskelupaikat
-
-
-
Buenos Aires, Argentiina, C1199ABB
- Aktiivinen, ei rekrytointi
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentiina, C1428AQK
- Rekrytointi
- Instituto Fleni
-
Buenos Aires, Argentiina, C1428
- Valmis
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentiina, 2900
- Rekrytointi
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Australia, 3004
- Valmis
- The Alfred Hospital
-
Parkwood, Australia, 4215
- Valmis
- Gold Coast University Hospital
-
-
-
-
-
Alicante, Espanja, 03010
- Aktiivinen, ei rekrytointi
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Espanja, 8035
- Valmis
- Hosp Univ Vall D Hebron
-
Bilbao, Espanja, 48013
- Aktiivinen, ei rekrytointi
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Espanja, 20014
- Valmis
- Hosp. Univ. Donostia
-
Madrid, Espanja, 28040
- Valmis
- Hosp. Clinico San Carlos
-
Seville, Espanja, 41009
- Aktiivinen, ei rekrytointi
- Hosp. Virgen Macarena
-
-
-
-
-
Seoul, Etelä -Korea, 05030
- Valmis
- Konkuk University Medical Center
-
Seoul, Etelä -Korea, 02447
- Valmis
- Kyunghee University Medical Center
-
Seoul, Etelä -Korea, 135-710
- Valmis
- Samsung Medical Center
-
-
-
-
-
Catania, Italia, 95123
- Valmis
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Italia, 16132
- Valmis
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Italia, 20144
- Valmis
- Casa di Cura del Policlinico
-
Milan, Italia, 20133
- Valmis
- Istituto Neurologico Carlo Besta
-
Naples, Italia, 80131
- Aktiivinen, ei rekrytointi
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Italia, 10043
- Valmis
- Aou San Luigi Gonzaga
-
Pavia, Italia, 27100
- Valmis
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Italia, 00168
- Valmis
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italia, 20086
- Valmis
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Asahikawa, Japani, 070-0901
- Aktiivinen, ei rekrytointi
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Japani, 113 8519
- Aktiivinen, ei rekrytointi
- Institute of Science Tokyo Hospital
-
Chiba, Japani, 260-8677
- Valmis
- Chiba University Hospital
-
Hamamatsu, Japani, 430-8558
- Aktiivinen, ei rekrytointi
- Seirei Hamamatsu General Hospital
-
Isehara, Japani, 259-1193
- Aktiivinen, ei rekrytointi
- Tokai University Hospital
-
Kobe, Japani, 650 0047
- Valmis
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Japani, 187-8551
- Aktiivinen, ei rekrytointi
- National Center of Neurology and Psychiatry
-
Koshigaya, Japani, 343-8555
- Aktiivinen, ei rekrytointi
- Saitama Medical Center
-
Kumamoto, Japani, 860-8556
- Valmis
- Kumamoto University Hospital
-
Nagoya, Japani, 466-8560
- Aktiivinen, ei rekrytointi
- Nagoya University Hospital
-
Nagoya, Japani, 455-8530
- Aktiivinen, ei rekrytointi
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Japani, 589 8511
- Valmis
- Kindai University Hospital
-
Sendai, Japani, 983-8520
- Aktiivinen, ei rekrytointi
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Japani, 321 0293
- Valmis
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Japani, 162-8666
- Valmis
- Tokyo Women's Medical University Hospital
-
Tenri, Japani, 632-0015
- Valmis
- Tenri Hospital
-
Toon-shi, Japani, 791-0295
- Valmis
- Ehime University Hospital
-
Toyama, Japani, 930-0194
- Valmis
- Toyama University Hospital
-
Ube, Japani, 755-8505
- Valmis
- Yamaguchi University Hospital
-
-
-
-
-
Ottawa, Kanada, K1N 6N5
- Rekrytointi
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Beijing, Kiina, 100191
- Valmis
- Peking University Third Hospital
-
Beijing, Kiina, 100034
- Valmis
- Peking University First Hospital
-
Beijing, Kiina, 100053
- Aktiivinen, ei rekrytointi
- Xuanwu Hospital ,Capital Medical University
-
Beijing, Kiina, 100070
- Aktiivinen, ei rekrytointi
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, Kiina, 130021
- Aktiivinen, ei rekrytointi
- The First Hospital of Jilin University
-
Changsha, Kiina, 410008
- Valmis
- Xiangya Hospital Central South University
-
Changsha, Kiina, 410008
- Aktiivinen, ei rekrytointi
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, Kiina, 610072
- Valmis
- Sichuan Provincial Peoples Hospital
-
Chifeng, Kiina, 024000
- Valmis
- Chifeng Municipal Hospital
-
Fuzhou, Kiina, 350001
- Aktiivinen, ei rekrytointi
- Fujian Medical University Union Hospital
-
Guangzhou, Kiina, 510080
- Aktiivinen, ei rekrytointi
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Kiina, 250012
- Aktiivinen, ei rekrytointi
- Qilu Hospital of Shandong University
-
Jinan, Kiina, 250014
- Valmis
- Qianfoshan hospital of Shandong Province
-
Nanchang, Kiina, 330006
- Aktiivinen, ei rekrytointi
- The First Affiliated Hospital of NanChang University
-
Shanghai, Kiina, 200336
- Valmis
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, Kiina, 200040
- Aktiivinen, ei rekrytointi
- Huashan Hospital Fudan University
-
Wuhan, Kiina, 430023
- Valmis
- Renmin Hospital of Wuhan University
-
Xi'an, Kiina, 710032
- Valmis
- Tangdu hospital the Fourth Military Medical
-
Xi'an, Kiina, 710075
- Aktiivinen, ei rekrytointi
- Xi 'an GaoXin Hospital
-
-
-
-
-
Floridablanca, Kolumbia, 681004
- Valmis
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Kolumbia, 50021
- Aktiivinen, ei rekrytointi
- Instituto Neurológico de Colombia
-
-
-
-
-
Athens, Kreikka, 12462
- Rekrytointi
- Attikon General Hospital of Athens
-
Athens, Kreikka, 11527
- Valmis
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Kreikka, 26504
- Valmis
- Patras University Hospital
-
Thessaloniki, Kreikka, 54636
- Rekrytointi
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Monterrey, Meksiko, 64710
- Valmis
- i Can Oncology Center
-
Tlalnepantla, Meksiko, 54055
- Rekrytointi
- Clinical Research Institute S.C.
-
-
-
-
-
Almada, Portugali, 2805-267
- Aktiivinen, ei rekrytointi
- Hospital Garcia de Orta
-
Braga, Portugali, 4710-243
- Valmis
- Hospital de Braga
-
Porto, Portugali, 4200 319
- Aktiivinen, ei rekrytointi
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Chorzów, Puola, 41 500
- Valmis
- Centrum Medyczne
-
Krakow, Puola, 30 539
- Valmis
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Puola, 20 093
- Valmis
- Prywatny Gabinet Lekarski
-
Poznan, Puola, 61 731
- Aktiivinen, ei rekrytointi
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Bordeaux, Ranska, 33000
- Valmis
- CHU Bordeaux
-
Bron, Ranska, 69699
- Valmis
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, Ranska, 94270
- Aktiivinen, ei rekrytointi
- Hopital de Bicetre
-
Marseille, Ranska, 13385
- Aktiivinen, ei rekrytointi
- Hopital de la Timone
-
Nice, Ranska, 06000
- Aktiivinen, ei rekrytointi
- Hopital PASTEUR
-
Nîmes, Ranska, 30029
- Aktiivinen, ei rekrytointi
- CHU Nimes Hopital Caremeau
-
Paris, Ranska, 75013
- Valmis
- Hopital de la Pitie Salpetriere
-
Paris, Ranska, 75019
- Valmis
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, Ranska, 67200
- Aktiivinen, ei rekrytointi
- CHRU Strasbourg
-
-
-
-
-
Berlin, Saksa, 13347
- Aktiivinen, ei rekrytointi
- Judisches Krankenhaus Berlin
-
Bochum, Saksa, 44791
- Valmis
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Saksa, 6120
- Aktiivinen, ei rekrytointi
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Saksa, 30625
- Aktiivinen, ei rekrytointi
- Medizinische Hochschule Hannover
-
Leipzig, Saksa, 4103
- Valmis
- Universitaetsklinikum Leipzig
-
Potsdam, Saksa, 14471
- Valmis
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Kaohsiung City, Taiwan, 88301
- Valmis
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Taiwan, 100
- Aktiivinen, ei rekrytointi
- National Taiwan University Hospital
-
Taipei, Taiwan, 111
- Aktiivinen, ei rekrytointi
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Hradec Králové, Tšekki, 500 05
- Aktiivinen, ei rekrytointi
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Tšekki, 708 52
- Valmis
- Fakultni Nemocnice Ostrava
-
Pardubice, Tšekki, 53203
- Valmis
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Birmingham, Yhdistynyt kuningaskunta, B15 2TH
- Valmis
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, Yhdistynyt kuningaskunta, EX2 5DW
- Valmis
- Royal Devon & Exeter Hospital
-
Glasgow, Yhdistynyt kuningaskunta, G514TF
- Aktiivinen, ei rekrytointi
- NHS Greater Glasgow and Clyde
-
London, Yhdistynyt kuningaskunta, NW3 2QG
- Valmis
- Royal Free Hospital
-
Sheffield, Yhdistynyt kuningaskunta, S10 2 JF
- Aktiivinen, ei rekrytointi
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
Colorado
-
Centennial, Colorado, Yhdysvallat, 80112
- Aktiivinen, ei rekrytointi
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, Yhdysvallat, 33067
- Valmis
- Healthcare Innovations Institute Inc
-
Maitland, Florida, Yhdysvallat, 32751
- Valmis
- Neurology Associates PA
-
Miami, Florida, Yhdysvallat, 33136
- Aktiivinen, ei rekrytointi
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, Yhdysvallat, 30912
- Valmis
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, Yhdysvallat, 66160
- Valmis
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21287
- Valmis
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02111
- Valmis
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, Yhdysvallat, 48073
- Valmis
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, Yhdysvallat, 64128
- Valmis
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, Yhdysvallat, 10032
- Valmis
- The Neurological Institute of New York
-
Patchogue, New York, Yhdysvallat, 11772
- Valmis
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, Yhdysvallat, 28204
- Valmis
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, Yhdysvallat, 44195
- Aktiivinen, ei rekrytointi
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78756
- Valmis
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Yhdysvallat, 53215
- Aktiivinen, ei rekrytointi
- Advocate Health - Aurora St. Luke's Medical Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Muut nimet:
|
|
Placebo Comparator: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Aikaikkuna: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Aikaikkuna: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Aikaikkuna: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Aikaikkuna: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Aikaikkuna: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Aikaikkuna: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Aikaikkuna: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Aikaikkuna: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Aikaikkuna: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Aikaikkuna: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Aikaikkuna: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Aikaikkuna: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Aikaikkuna: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Aikaikkuna: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Aikaikkuna: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Aikaikkuna: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Aikaikkuna: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Hermoston sairaudet
- Patologiset prosessit
- Neuromuskulaariset sairaudet
- Krooninen sairaus
- Sairauden ominaisuudet
- Autoimmuunisairaudet
- Immuunijärjestelmän sairaudet
- Ääreishermoston sairaudet
- Hermoston autoimmuunisairaudet
- Demyelinisoivat sairaudet
- Polyneuropatiat
- Polyradikuloneuropatia
- Patologiset tilat, merkit ja oireet
- Polyradikuloneuropatia, krooninen tulehduksellinen demyelinisaatio
Muut tutkimustunnusnumerot
- CR109195
- 80202135CDP3001 (Muu tunniste: Janssen Research & Development, LLC)
- 2021-003234-37 (EudraCT-numero)
- 2023-508425-28-00 (Rekisterin tunniste: EUCT number)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .